Retatrutide for Sleep Apnea: What the New Trials Show and What You Can Do Now

Retatrutide for sleep apnea worked in two Phase 3 trials of adults with moderate-to-severe obstructive sleep apnea (OSA) and excess weight. Higher doses cut breathing events by 25–34 an hour versus 10 on placebo at 80 weeks. It isn't FDA-approved. Access is through trials or narrow expanded access. Zepbound is approved for moderate-to-severe OSA in adults with obesity.

The trial with type 2 diabetes showed smaller drops, and neither trial tested stopping CPAP.

About half the people in the 9 mg group without diabetes met the trial's target: no sleep apnea, or mild sleep apnea without excessive daytime sleepiness. The table below shows each group's results — and why the "60%" headline you may have seen is a different number.

RX Index Decision Verdict: If your sleep apnea needs treatment now, don't wait for retatrutide. Keep using prescribed CPAP, and ask whether Zepbound fits: it's approved for moderate-to-severe obstructive sleep apnea in adults with obesity.

• Best for (following retatrutide): people whose sleep apnea is already well treated and who want to know what's coming.
• Not ideal for: anyone untreated or struggling now, and anyone thinking about buying "research" retatrutide online.
• The factor that matters most: whether your sleep apnea is treated tonight — not which drug wins a trial.

Retatrutide for sleep apnea: what the two trials found

In two Phase 3 trials, adults with moderate-to-severe obstructive sleep apnea (OSA) and excess weight had far fewer breathing events on retatrutide than on placebo after 80 weeks. The trial without diabetes showed larger drops: the 9 mg and 12 mg doses cut about 32 to 34 events an hour, versus about 10 on placebo. In the trial with type 2 diabetes, those doses cut about 25 events an hour.

First, the one number that runs this whole page. AHI (apnea-hypopnea index) is how many times an hour your breathing stops or gets very shallow while you sleep. Under 5 is normal. 5 to under 15 is mild. 15 or more is moderate to severe.

People in these trials started at an average AHI of about 56 to 59. That's like a smoke alarm going off almost once a minute, all night.

Here's what happened by week 80. The numbers come straight from the NEJM paper (Grunstein et al., October 2026). Both drug and placebo groups also received diet and activity counseling.

*"Mild or no sleep apnea" means AHI under 5, or AHI 5 to 14 without excessive daytime sleepiness (an Epworth Sleepiness Scale score of 10 or less). The percentages are estimates from the trial's statistical model. It's not a cure rate, and it doesn't mean anyone stopped CPAP.

A few notes so the table reads right:

• The trial's main question was the 9 mg and 12 mg doses. The 4 mg dose also passed the statistical test for its drop in AHI events per hour. Its other results in this table did not pass the trial's strict testing rules.

• "Oxygen-drop burden" (sleep apnea–specific hypoxic burden) measures how deep and long your oxygen dips are, not just how many. It's tied to heart risk.

• Weight came down too: 12.5% to 22.2% without diabetes and 12.1% to 18.5% with diabetes, depending on dose, versus about 5% on placebo.

• These are group results. They're not doses to pick or a forecast for you. The trials did not establish a best dose.

The honest catch: even in the group with the highest target rate, about half did not reach it at 80 weeks. Missing that target can mean more than mild sleep apnea, or mild sleep apnea with daytime sleepiness. Retatrutide reduced sleep apnea. It didn't erase it for everyone.

If your mask is the problem, ask your sleep clinician about its fit or other treatments. You don't need to wait for retatrutide to get that help.

Waiting is a fine choice if your sleep apnea is already treated. It just isn't a treatment plan. The right GLP-1 path isn't the same for everyone. It depends on your state, your insurance and its covered-drug list (formulary), whether you want an FDA-approved or compounded medicine, a shot or a pill, and your budget. The RX Index's Find My GLP-1 Path tool asks a few quick questions and shows the GLP-1 paths and providers that fit your goals, budget, insurance, and situation. It's free, takes about 2 minutes, and needs no signup. It does not confirm retatrutide access; compounded medicines and pills do not share Zepbound's sleep apnea approval.

See which GLP-1 path fits you

Who was in these trials (and does that sound like you?)

The trials enrolled adults with a past sleep apnea diagnosis, an AHI of 15 or more on an overnight lab sleep study at screening, and a BMI of 27 or higher. BMI (body mass index) is a measure based on height and weight. In practice they were heavier than that floor: average BMI in most groups ran about 40 to 44. About 3 in 10 used PAP (positive airway pressure, like a CPAP machine) when they started.

Per the TRIUMPH-1 trial record, people not on PAP had to be unable or unwilling to use it. People on PAP had to have used it for at least 3 months.

This research is closest to you if:

• You have moderate or severe obstructive sleep apnea confirmed by a sleep study.

• Your BMI is 27 or higher.

It doesn't tell you much if:

• You have mild sleep apnea.

• You have central sleep apnea (a brain-signal problem, not a blocked airway).

• You've never had a sleep study.

Why headlines say "60%" — which number is right?

All of these numbers are real. They count in different ways. In June, Lilly announced a 36.1-event (60.6%) drop using an "if everyone stayed on the drug" estimate. The October paper leads with a different method, and a third follows the groups people were assigned to, even if treatment changed.

Think of a class average. One question is how the whole class did, even if some students left. Another is how the class might have done if everyone had stayed. The second needs an estimate; it isn't just an average of the finishers. Both answer different questions.

Want the long version of how trials count results? See how to read GLP-1 clinical trials.

Can you get retatrutide for sleep apnea now?

Not as a regular prescription. Retatrutide isn't FDA-approved for any use; trials and a narrow, doctor-requested expanded-access program have separate rules. The FDA says it cannot be used in compounding under federal law. Lilly says it cannot be legally sold or marketed for human use.

No page, including this one, can tell you when it will reach pharmacies. Here's what is known as of October 24, 2026.

When could it be approved?

In July 2026, Lilly said its trial results support retatrutide as a potential treatment for obesity, knee arthritis pain, and obstructive sleep apnea. It said it plans to file for FDA approval in the first quarter of 2027.

A filing is a request, not an approval. FDA review and a decision come next; pharmacy access and insurance coverage would depend on approval and later decisions. Lilly hasn't announced an approval date or a retail price. For new updates, see retatrutide news today.

Can you join a trial?

The two sleep apnea trials are finished. In our October 24, 2026 ClinicalTrials.gov search, the only Lilly-sponsored retatrutide record marked "Recruiting" was SYNERGY-Outcomes, a fatty liver study. Confirm screening and eligibility with the study team; the registry status alone doesn't promise either.

There is also a narrow, doctor-requested expanded-access program for adults with severe obesity. Its registry record was listed as available when we checked; the record's last update was August 6, 2026. All five requirements apply:

• Age 18 or older

• A BMI of 35 or higher despite taking and tolerating the highest available dose of a long-term weight medicine

• At least two serious or life-threatening obesity-related health problems already under standard care

• No suitable, reasonably accessible trial of retatrutide or a comparable experimental medicine

• Discussion with your doctor of all standard options, including weight-loss surgery

A medical reason not to take retatrutide rules someone out. Your own doctor must request access; availability also depends on location, supply, and an individual review.

Sleep apnea alone doesn't qualify you. Details: retatrutide trials tracker and who qualifies for retatrutide outside a trial.

What about "research" retatrutide sold online?

The FDA has warned companies selling retatrutide labeled "for research purposes" or "not for human consumption." Their quality is unknown, and the FDA says they may be harmful. A vial sold online as a research product is not verified as the medicine tested in these trials. Nobody can promise what's in it.

If you used one and feel unwell, call Poison Control at 1-800-222-1222. Call 911 for trouble breathing, collapse, a seizure, or someone who can't be awakened. More: can you get compounded retatrutide? and how to avoid fake GLP-1 medications.

Retatrutide vs Zepbound for sleep apnea

No trial has tested retatrutide against Zepbound (tirzepatide) for sleep apnea. Each was tested against placebo, in trials that differed in length, who could join, and how results were counted. Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity; retatrutide isn't approved for anything.

Here's the side-by-side. We pulled it from the retatrutide NEJM paper, the original SURMOUNT-OSA paper, Lilly's Zepbound sleep apnea trial data, and the FDA approval announcement.

*The same combined target applies: AHI under 5, or AHI 5 to 14 with an Epworth Sleepiness Scale score of 10 or less. These are not cure rates. All methods use estimates for missing results; the weight ranges for retatrutide include all three studied doses.

Why you can't crown a winner from this table:

• Retatrutide got 28 more weeks to work.

• Its trials used a BMI floor of 27; the Zepbound trials generally used 30, except in Japan.

• They used a different counting method.

• They mixed PAP users and non-users in one trial instead of splitting them.

The Zepbound trials excluded type 2 diabetes. Its approved sleep apnea indication does not exclude it; the current label and your full health history guide that decision.

Lilly's head-to-head trial of the two drugs (TRIUMPH-5) measures weight; its registered outcomes do not include sleep apnea.

Our honest read: both drugs cut sleep apnea a lot. Only one has passed FDA review for it. For how the two compare on weight, see retatrutide vs tirzepatide.

What you can do for sleep apnea now

If you have moderate-to-severe obstructive sleep apnea and obesity, Zepbound is FDA-approved to treat it, alongside a reduced-calorie diet and more activity. CPAP holds the airway open while you use it. If your sleep apnea is mild, untested, or might be central, start with a sleep study or sleep doctor.

Three quick questions to find your row:

1. Has a sleep study shown an AHI of 15 or more?
2. Is your BMI 30 or higher?
3. Do you have commercial insurance, Medicare, or Medicaid?

Don't know your AHI or BMI? Bring your sleep study report and ask your clinician to confirm. Don't guess your way into a row.

Say you're 54. Your last sleep study showed obstructive sleep apnea with an AHI of 41, your BMI is 34, you hate your mask, and you have insurance through work. Those diagnosis and BMI details match Zepbound's sleep apnea indication; your clinician still needs to check your health history. You don't need to wait for retatrutide to ask about it.

On Medicare? CMS's June 10, 2026 Bridge FAQ directs Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity through regular Part D, not the $50 Bridge. Your plan's prior-authorization and formulary-exception rules still apply. People with a Part D-coverable use aren't eligible for the Bridge, which runs July 1, 2026 to December 31, 2027 for weight management. Details: does Medicare cover Zepbound?

What it costs if you pay cash (Ro's pricing page and Lilly's offer terms, checked October 24, 2026):

• Zepbound KwikPen: $299 (2.5 mg) and $399 (5 mg), per 28-day pen. For 7.5 mg to 15 mg it's $449 under Lilly's offer terms. After the first qualifying purchase, each refill must be bought within 45 days of receiving the previous fill to keep that offer. Without it, Lilly lists $499 for 7.5 mg and $699 for 10, 12.5, or 15 mg. Eligibility rules apply; taxes or extra fees may apply. Some fills may need a reimbursement claim to receive the savings.

• Ro membership: $39 the first month, refunded if you're not eligible for GLP-1s. Then $149 a month on the monthly plan, or an advertised $74 a month equivalent with a 12-month plan paid up front. That is $888 for the annual membership period by our math (12 × $74); we did not verify the checkout total. The introductory month is separate.

• Billing: Medication and membership are two separate charges.

• What's included and extra: Membership includes provider care, insurance support, and lab testing when needed. Ro's terms allow extra lab charges and charge $15 for each consultation beyond 24 a year. KwikPen needles are not included in the pen pack; ask the pharmacy about supplies and any extra fees.

• Renewal and refunds: Ro's terms say paid membership fees are nonrefundable, apart from the stated ineligibility refund above. Cancel at least 48 hours before renewal to avoid another membership charge.

• Price match: Ro says its cash prices match LillyDirect, NovoCare, and TrumpRx.

The lower-dose prices are not the maintenance cost for sleep apnea: Zepbound's label lists 10 mg or 15 mg as OSA maintenance doses. That explains the price range; your prescriber chooses treatment.

For every dose and offer rule, see Zepbound for sleep apnea and cheapest Zepbound without insurance.

Ro does not offer retatrutide. Its free insurance checker can report what your plan says about Zepbound. Ro's insurance support is for Zepbound autoinjector pens, separate from the cash-pay KwikPen prices above. Its insurance team verifies benefits and handles the paperwork, including prior authorization, if a Ro-affiliated clinician prescribes treatment. Prior authorization is a permission slip from your insurer before it agrees to pay. If you'd rather not pay a membership, your own doctor can prescribe Zepbound and file that paperwork too.

If you have commercial insurance and a sleep study showing moderate-to-severe sleep apnea, find out what your plan says before you pay cash. The check gives you a report, not an approval. A licensed clinician still decides if Zepbound fits you.

On Medicare or Medicaid? Start with your own plan and doctor instead. Denied already? See how to appeal a Zepbound denial and does insurance cover Zepbound for sleep apnea?

Could retatrutide replace your CPAP?

The trials weren't built to answer that. People who used PAP paused it for 7 to 9 days before each sleep test under trial supervision, so researchers could measure breathing without PAP's effect. The paper says effects on PAP use weren't measured. Whether anyone can stop CPAP is a call for a sleep doctor, usually after a repeat sleep study.

CPAP holds your airway open while you use it. A weight-loss medicine changes the trend over months. They aren't rivals.

One trap is worth knowing. If your CPAP app shows almost zero events, that's your breathing with the machine working. It doesn't tell you what happens without it. Only a sleep test off the machine answers that, and only your sleep doctor should set one up.

If you're nodding off while driving, pull over safely, don't keep driving, and seek prompt medical advice. If someone sees you gasping in your sleep, arrange a medical assessment. Don't wait for a new drug.

What side effects showed up in the sleep apnea trials?

Stomach and gut problems were the most common reported problems, especially diarrhea and nausea. Some people had odd skin sensations, called dysesthesia. The paper records adverse events—health problems during the trial, whether or not the drug caused them. Serious adverse events were reported at similar overall rates on retatrutide and placebo, though individual dose groups varied. These small groups cannot establish equal safety or rank doses by safety.

These numbers come from the NEJM paper's sleep apnea groups themselves, not the bigger weight-loss trials. "Serious" refers to outcomes such as hospitalization, a life-threatening event, disability, or death—not just how intense a symptom felt.

*This Table 3 category includes deaths; the paper's trial-disposition narrative lists deaths separately. There were three deaths in the placebo groups and one in a retatrutide group (upper gastrointestinal bleeding). That does not show the drug caused the death. Numbers this small can't show whether the drug is safer or riskier.

Heart rate rose too. It peaked about 5 to 7 beats a minute above where it started, then settled to about 1 to 2 beats higher by week 80.

Retatrutide has no FDA-approved prescribing label yet. Trials and expanded access still have medical exclusions — another reason this isn't a do-it-yourself medicine. More: retatrutide side effects.

What these trials can't tell you yet:

• Whether the benefit lasts after stopping

• Whether it lowers heart attacks or strokes (a separate outcomes trial is still running)

• How it works for people with a BMI under 27

• How it works for people with lots of daytime sleepiness, since sleep-related symptoms were low to mild on average at the start

In the trial without diabetes, the sleep-related daily-life score didn't clear the trial's statistical bar; in the diabetes trial, the 9 mg and 12 mg results did. Lilly funded the research and helped design and analyze it.

Take this to your next appointment

A short list keeps a 15-minute visit on track. Copy these and bring your sleep study report, your treatment details, your medication list, and your insurance card. If you don't know something, write "unknown" — don't guess.

What we actually verified

Last verified October 2026; source checks completed October 24, 2026:

• The full NEJM retatrutide sleep apnea paper and supplement (DOI 10.1056/NEJMoa2611477), read through a public copy of the original paper

• The original NEJM SURMOUNT-OSA paper (DOI 10.1056/NEJMoa2404881)

• ClinicalTrials.gov records for TRIUMPH-1, TRIUMPH-2, expanded access, SYNERGY-Outcomes, TRIUMPH-5, and TRIUMPH-Outcomes, plus a search for recruiting retatrutide studies

• Lilly's June 6 and July 23, 2026 announcements

• The FDA's Zepbound sleep apnea approval and its unapproved-GLP-1 page (content current as of October 1, 2026)

• The current Zepbound label (revised August 2026) and Lilly's Zepbound sleep apnea trial data

• CMS's Medicare GLP-1 Bridge FAQ (June 10, 2026) and current program page

• Ro's pricing, insurance, free-checker, and membership terms, plus Lilly's KwikPen offer terms

• NIH sleep apnea guidance, federal driving-safety advice, and Poison Control's emergency guidance

What we didn't do:

• Test any medicine

• Check anyone's eligibility or insurance

• Complete a Ro checkout

Ro's prices and price-match claim are Ro's own statements. The $888 annual membership figure is our calculation from its advertised rate, not a checked payment-screen total. We didn't confirm a launch date, a retail price for retatrutide, or what any study or expanded-access program charges.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

How we evaluate providers: our methodology.

Retatrutide and sleep apnea FAQ

Can a GLP-1 medicine help me stop using CPAP?

The drugs studied here reduced sleep apnea, but these trials did not test when patients could safely stop CPAP. Keep using prescribed CPAP until your sleep clinician reassesses your treatment and advises a change; a repeat sleep study may be needed.

My CPAP app shows almost no events. Is my sleep apnea gone?

That reading shows your breathing while the machine is treating it. It doesn't show what happens without it. Ask your sleep doctor whether a re-check makes sense.

Why would insurance deny Zepbound if it's approved for sleep apnea?

FDA approval and your plan's decision to pay are separate. Plans can still require prior authorization, a sleep study, or other records. Ask for the exact reason in writing, then see how to appeal a Zepbound denial.

If I join a trial, can I keep getting retatrutide afterward?

Don't assume so. Ask the study team about care and access after the study ends before you sign up. Expanded access is a separate program with strict rules.

Does retatrutide cause obstructive sleep apnea?

These trials studied people who already had OSA; they were not designed to rule out new-onset OSA. In two Phase 3 trials, people with sleep apnea had fewer breathing events on retatrutide than on placebo.

Does Eli Lilly have retatrutide for obstructive sleep apnea?

Lilly has tested it for sleep apnea in two finished Phase 3 trials and says the results support it as a potential treatment. In July 2026, Lilly said it planned to file for FDA approval in early 2027; retatrutide still has no approval or routine pharmacy access. Trials and narrow expanded access have separate rules. Lilly's approved medicine for moderate-to-severe OSA in adults with obesity is Zepbound.

Does Zepbound treat obstructive sleep apnea?

Yes. The FDA approved Zepbound on December 20, 2024 to treat moderate-to-severe obstructive sleep apnea in adults with obesity, alongside diet and activity.

What is obstructive sleep apnea?

Your airway narrows or closes over and over while you sleep, so your breathing stops or gets shallow. Doctors measure it with the AHI. 15 or more events an hour is moderate to severe.

Does retatrutide affect sleep or cause insomnia?

Insomnia was not listed among adverse events reported by at least 10% of participants in any group in the sleep apnea paper. That does not establish that it cannot occur. The common problems were diarrhea, nausea, and other gut problems.

Is retatrutide better than Zepbound for sleep apnea?

Nobody knows yet. No trial compared them for sleep apnea, and their trials differed in length, who joined, and how results were counted.

Did retatrutide work for people with type 2 diabetes and sleep apnea?

Yes, though average drops were smaller than in the trial without diabetes. On 9 mg and 12 mg, AHI fell about 25 events an hour versus about 10 on placebo. About 39% reached no sleep apnea, or mild sleep apnea without excessive daytime sleepiness, versus about 13% on placebo.

Does retatrutide cure sleep apnea?

No study shows a cure. About half in the 9 mg group without diabetes reached no sleep apnea, or mild sleep apnea without excessive daytime sleepiness, at 80 weeks. Whether that lasts after stopping wasn't tested.

What dose of retatrutide was studied for sleep apnea?

The trials tested 4, 9, and 12 mg once a week, with the main question on 9 and 12 mg. These are research doses, not instructions. There's no approved retatrutide dose.

Are "peptides for sleep apnea" sold online safe?

Retatrutide sold as a "research peptide" isn't an approved medicine, and the FDA says such products' quality is unknown and may be harmful. Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity.

Still not sure which GLP-1 path fits you? Take The RX Index's free Find My GLP-1 Path quiz — about 2 minutes, no signup.

Sources

1. Grunstein RR, et al. Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea. New England Journal of Medicine, published October 21, 2026; presented at the European Sleep Research Society congress, October 20–23, 2026. Full paper and supplement read through a public copy of the original. Checked October 24, 2026.
2. ClinicalTrials.gov. TRIUMPH-1, NCT05929066 and TRIUMPH-2, NCT05929079. Checked October 24, 2026.
3. Eli Lilly. June 6, 2026 release (TRIUMPH-1 sleep apnea topline, efficacy estimand). Checked October 24, 2026.
4. Eli Lilly. July 23, 2026 release (submission plans; legal status). Checked October 24, 2026.
5. U.S. FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, content current as of October 1, 2026. Checked October 24, 2026.
6. U.S. FDA. FDA Approves First Medication for Obstructive Sleep Apnea, December 20, 2024. Checked October 24, 2026.
7. Eli Lilly. Zepbound prescribing information, revised August 2026. Checked October 24, 2026.
8. Eli Lilly. Zepbound SURMOUNT-OSA clinical data. Checked October 24, 2026.
9. CMS. Medicare GLP-1 Bridge Expectations and FAQs, June 10, 2026. Checked October 24, 2026.
10. Ro. Weight loss pricing, insurance, free insurance checker, and terms of use (revised April 2, 2026). Checked October 24, 2026; no checkout completed.
11. ClinicalTrials.gov. Expanded access, NCT07629401 (last updated August 6, 2026), SYNERGY-Outcomes, NCT07165028, TRIUMPH-5, NCT06662383, and TRIUMPH-Outcomes, NCT06383390. Records checked through the public registry API on October 24, 2026. The RX Index's retatrutide clinical trials tracker has broader trial guidance.
12. Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine, published June 21, 2024; updated July 1, 2024. Original full-text PDF, checked October 24, 2026.
13. Eli Lilly. Zepbound savings and purchase-offer terms. Checked October 24, 2026.
14. CMS. Medicare GLP-1 Bridge. Checked October 24, 2026.
15. NHLBI, NIH. Living with sleep apnea, treatment, diagnosis, and symptoms. Checked October 24, 2026.
16. NHTSA. Drowsy driving and Driving When You Have Sleep Apnea. Checked October 24, 2026.
17. National Capital Poison Center. Poison Control. Checked October 24, 2026.
18. FDA. Investigator Responsibilities—Safety Reporting for Investigational Drugs and Devices, December 2025, definitions on pages 3–5. Checked October 24, 2026.
19. CMS. State Prescription Drug Resources, updated October 22, 2026. Checked October 24, 2026.